This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
- Subjects diagnosed at study visit or within 3 months of visit with OH
- OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)
- No prior treatment for OH or OAG
- No prior ocular surgery or history of ocular trauma
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada | |||
| Official Title | Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada | |||
| Brief Summary | This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada. | |||
| Detailed Description | Not Provided | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Cohort Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | Canadian population | |||
| Condition |
| |||
| Intervention | Other: There is no intervention in this study. This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada. | |||
| Study Groups/Cohorts | There is no intervention in this study This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada. Intervention: Other: There is no intervention in this study. | |||
| Publications * | Not Provided | |||
| * Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 410 | |||
| Original Enrollment | 400 | |||
| Actual Study Completion Date | April 2009 | |||
| Actual Primary Completion Date | April 2009 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Canada | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00334750 | |||
| Other Study ID Numbers | A6111125 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | September 2010 | |||
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
